Johnson & Johnson said that a real-world study showed its single shot COVID-19 vaccine protects against breakthrough infections and hospitalizations for up to six months.
The study, sponsored by the vaccine developer, was conducted between January 1 and September 7 last year, before the Omicron variant was discovered. It is also yet to be peer-reviewed.
J&J said protection against infection from its single dose vaccine starts to wane only from the fourth month compared to the second month in the case of two-dose vaccines from rivals Pfizer Inc and BioNTech's as well as Moderna .
No waning of protection was found for ICU admissions for all the three vaccines, J&J said. The company said the study was carried out by collecting claims and laboratory data covering 168 million people.
British PM Starmer to send four Typhoon jets to Qatar
Bombing of Tehran intensifies as war enters day six
Azerbaijan vows to respond after four injured by Iranian drones
72 killed in Israeli attacks on Lebanon as it warns residents to leave south
Nepal goes to the polls; voters seek change after youth-led protests
Landslide kills over 200 people at Congo's Rubaya mine
80 people killed after US sinks Iranian warship
Emergency GCC-EU meeting to discuss Iranian aggression
